Thymosin Alpha-1 Dosage in the Research Literature

Reading Thymosin alpha-1 dosage protocols from the trial record

Thymosin alpha-1 dosage in the published trial record is unusually consistent. The standard branded regimen — used in the hepatitis approval-anchoring trials — is 1.6 mg subcutaneously twice weekly ^[20]. Sepsis trials use the same 1.6 mg subcutaneous unit dose but compress the schedule (twice daily for 5 days, then daily for 2 days) ^[6]. Oncology adjuvant trials have varied dose and schedule. Vaccine-adjuvant protocols use lower doses (900 μg twice weekly × 4 weeks) ^[18]. All approved-indication trials use subcutaneous administration; oral bioavailability is essentially zero because the peptide is hydrolyzed in the gastric environment.

Published Dosing Protocols

The published dosing protocols cluster into five regimens:

1. Chronic hepatitis B and C: 1.6 mg subcutaneously twice weekly for 6 months ^[12][13][14].
2. Severe sepsis (ETASS protocol): 1.6 mg subcutaneously twice daily for 5 days, then 1.6 mg subcutaneously once daily for 2 days ^[6].
3. Severe COVID-19: 1.6 mg subcutaneously once daily, with earlier initiation associated with stronger mortality signal ^[8][9].
4. Influenza vaccine adjuvant (Gravenstein 1989): 900 μg subcutaneously twice weekly for 4 weeks plus inactivated influenza vaccine ^[18].
5. Post-transplant immune reconstitution (Perruccio 2010): 1.6 mg subcutaneously twice weekly post-transplant ^[19].

Reported Dose Ranges

Trial doses range from 900 μg to 16 mg subcutaneously, with 1.6 mg twice weekly the most commonly studied unit dose in chronic indications ^[20]. Higher unit doses appear in early-phase oncology adjuvant studies; no dose-limiting toxicity has been reported up to 16 mg subcutaneous. The 1.6 mg dose anchors the Zadaxin label-equivalent regimen and has been the comparator dose for most subsequent trials.

Acute Illness Dosing Protocols in the Literature

<a id="acute-illness"></a>For thymosin alpha 1 dosage when sick, the published acute-illness protocols are the sepsis and COVID-19 regimens — both intentionally front-loaded relative to the chronic hepatitis schedule. The ETASS sepsis trial protocol administered 1.6 mg subcutaneously twice daily for the first 5 days then once daily for 2 days, total 7 days ^[6]. The Liu 2020 Wuhan COVID-19 cohort administered 1.6 mg subcutaneously once daily ^[8]; the Sun 2021 critical-COVID-19 study used the same daily dosing with earlier initiation favored ^[9].

These are inpatient protocols administered under medical supervision in trial settings. They are described here as documented trial protocols, not as a recommendation for outpatient acute use.

Treatment Duration in the Literature

Hepatitis B and C trials typically dosed for 6 months ^[12][14]. The ETASS sepsis protocol ran 7 days ^[6]. Influenza-vaccine-adjuvant protocols ran 4 weeks ^[18]. Post-transplant immune-reconstitution dosing in the Perruccio cohort extended across the post-transplant recovery window ^[19]. No consensus protocol exists for non-trial outpatient use; the durations above reflect the documented trial designs.

Pharmacokinetics and Half-Life

<a id="pharmacokinetics"></a><a id="half-life"></a>Plasma elimination half-life after subcutaneous administration is approximately 2 hours in healthy adults, as documented in the Billich 2001 pharmacy monograph and the underlying Zadaxin development PK work ^[20]. Biological immunomodulatory effect persists 48–72 hours — the rationale for the twice-weekly hepatitis schedule despite the short plasma half-life. Receptor engagement (TLR-9 / TLR-2 on dendritic cells) initiates downstream T-cell and cytokine cascades that outlast plasma presence by orders of magnitude ^[4][5].

A 2025 preclinical study in Drug Delivery (Hu et al.) reported development of an in-situ-forming liquid-crystal depot intended to extend Tα1 subcutaneous dosing intervals beyond twice-weekly — an in vitro release-profile study, not a clinical trial ^[24].

Routes of Administration in Studies

<a id="administration"></a>Subcutaneous injection is the standard route in every approved-indication trial ^[20]. Intravenous administration has appeared in early-phase exploratory work but is not the standard. Intramuscular administration appears in some legacy formulations. Oral administration has been investigated preclinically but is not bioavailable — the synthetic peptide is hydrolyzed in the gastric environment.

How Thymosin Alpha-1 Is Administered in Trials

Subcutaneous injection of the reconstituted lyophilized synthetic peptide is the standard. Reconstituted product is intended for prompt administration per the Zadaxin product label ^[20]. Injection sites in the published trials are typically abdomen or thigh; injection-site discomfort and transient erythema are the most commonly reported adverse events across the published Zadaxin program.

Timing of Administration

Most trials administered without regard to circadian timing; twice-weekly dosing was selected based on the peptide's pharmacokinetic half-life and the duration of downstream biological effect rather than on chronobiology ^[20]. The sepsis twice-daily-for-5-days protocol is exposure-driven: it maintains dendritic-cell receptor engagement across the critical early window of sepsis-induced immune suppression ^[6].